2007: Spondylarthropathies and Psoriatic Arthritis: Treatment II
Search or Browse by Day

Spondylarthropathies and Psoriatic Arthritis: Treatment II

1153
Infliximab Improves Spinal Mobility in Patients with Ankylosing Spondylitis: Two-Year Findings from the ASSERT Clinical Trial
1154
Sustained Reduction in Spinal Inflammation in Patients with Ankylosing Spondylitis after Treatment with Infliximab
1155
The Efficacy of Combination Methotrexate and Infliximab in Patients with Ankylosing Spondylitis: A Clinical and Magnetic Resonance Imaging Correlation
1156
Psoriasis Occurrence or Reactivation under Anti TNF aAlpha Therapy. A Case Series
1157
New Onset Uveitis in Ankylosing Spondylitis Patients Treated with Anti-TNF Therapy
1158
Adalimumab Significantly Reduces Inflammation in the Spine and Sacroiliac Joints in Active Ankylosing Spondylitis
1159
Adalimumab is Effective and Well-Tolerated in Treating Ankylosing Spondylitis (AS) in Real-Life Clinical Practice: The RHAPSODY Trial
1160
Long-Term Spinal Mobility in Ankylosing Spondylitis (AS) Patients Treated with Adalimumab: 104-Week Results from ATLAS
1161
Long Term Efficacy and Safety, Including Reports of Ocular Inflammation, in Ankylosing Spondylitis Patients Treated with Etanercept for 4 Years
1162
Evidence-Based Recommendations for the Management of Ankylosing Spondylitis: Results of the 3e Initiative in Rheumatology Involving a Broad Panel of Experts and Practicing Rheumatologists
1163
Gait Parameters are Responsive to Change in Function Associated with TNFα Blockade in People with Ankylosing Spondylitis
1164
Complementary and Alternative Medicines in Ankylosing Spondylitis
1165
CANaDian evaluation of Low DosE Infliximab in Ankylosing Spondylitis (CANDLE)-12 week Magnetic Resonance Imaging Evaluation of Spinal Inflammation with the SPARCC MRI Method
1166
How Should We Define the Patient Acceptable Symptom State (PASS): Acceptable for a Few Months or Acceptable for Life?
1167
Linear Definition of the Edmonton Ankylosing Spondylitis Metrology Index (EDASMI) and Comparison with the BASMI 0-2 and 0-10 indices
1168
When B27-positive Boys Grow Up: The Differing Clinical Courses of Juvenile- and Adult-Onset Spondyloarthritis
1169
The Oswestry Disability Questionnaire Assesses Activity and Function Domains in Ankylosing Spondylitis
1170
The Diagnostic Value of Scintigraphy in Assessing Sacroiliitis in Ankylosing Spondylitis and Patients with Clinically Probable Sacroiliitis- A Systematic Literature Research
1171
Urinary CTX-II is Associated with Radiological Damage and Progression in Patients with Ankylosing Spondylitis
1172
Mechanism of Action of Heat Shock Protein Derived Peptide Epitopes in Ankylosing Spondylitis
1173
The Relationship of Clinical Features and Laboratory Measurements to Radiological Damage in a Turkish Cohort of Patients with Ankylosing Spondylitis- A Cross Sectional Study
1174
Infliximab in Severe Active Ankylosing Spondylitis with Spinal Ankylosis
1175
Differences between HLA-B27 Positive and Negative Patients with Ankylosing Spondylitis. Data From a Large Registry of Patients
1176
Persistent Disease Activity Patterns Predominate in Ankylosing Spondylitis (AS) and are Associated with Worse Clinical Outcomes
1177
The changes of aortic root predict Ankylosing Spondylitis in Korean patients by Transesophageal Echocardiography
1178
Clinical and Laboratory Findings of Patients with Familial Mediterranean Fever associated Ankylosing Spondylitis (FMF-AS)
1179
Impact of Ankylosing Spondylitis on Work and Family Life: Comparisons with the U.S. Population
1180
Which Aspects of Functioning are Relevant for Patients with Ankylosing Spondylitis: Results of a Focus Group Interviews
1181
Adalimumab Is Effective in Treating Patients with Psoriatic Arthritis (PsA) in Real-Life Clinical Practice: The STEREO Trial
1182
Prediction of Time to Relapse After Withdrawal of Etanercept in Psoriatic Arthritis
1183
Health Related Quality of Life Following TNFα Inhibitors Improves More in Psoriatic Arthritis Compared to Rheumatoid Arthritis Patients
1184
Bone Mineral Density and Prevalence of Osteoporosis and Fractures in Psoriatic Arthritis
1185
Measures Associated with Disease Activity in Psoriatic Arthritis
1186
Composite Indices For Disease Activity in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA)
1187
Burden of Ankylosing Spondylitis and Psoriatic Arthritis on Work Capability, Physical Function and Quality Of Life
1188
A Comparative Study of Axial Forms of Psoriatic Artritis with Primary Ankylosing Spondylitis. Are Activity Parameters of as Useful in Axial Psa?
1189
Utility of Radiological Criteria for the Classification and Evaluation of Axial Psoriatic Arthritis
1190
Radiographic Spinal Damage and Spinal Mobility Correlate Poorly in Psoriatic Spondylitis (Ps-Sp)
1191
Clinical Outcome Measures in Psoriatic arthritis (PsA): Comparing Enrollment and Response in a Biologics Study
1192
Osteoclast Precursor Numbers from Peripheral Blood Following Cytokine Stimulation are Increased in Psoriatic Arthritis Patients with Arthritis Mutilans Defined Radiographically
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>